At what enterprise value was ERGOMED acquired in 2023?

You can find the full valuation details of ERGOMED on mynth capital. The transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b GBP. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of ERGOMED when it was acquired by PERMIRA?

The estimated EV/EBITDA multiple for ERGOMED is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was ERGOMED acquired by PERMIRA?

ERGOMED was acquired by PERMIRA in 2023.

What was the EBITDA of ERGOMED during the acquisition?

ERGOMED's EBITDA is estimated to be in the range of 25M - 50M GBP. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the ERGOMED acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the ERGOMED deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.unquote.com/uk/official-record/3029938/permira-to-take-ergomed-private-for-gbp-703m

← DATABASE

Home Database Healthcare & PharmaERGOMED

09/2023

ERGOMED acquired by PERMIRA

UNITED KINGDOM Healthcare Services / CRO / Clinical Trials EV 500M - 1.5b GBP

Context

Permira acquired Ergomed in a recommended cash offer, taking the company private from the London Stock Exchange (AIM). The transaction was driven by the thesis that Ergomed's next phase of growth—requiring significant investment in technology and international expansion (particularly in the US)—could be better executed away from the public markets. The deal structure allowed the founder, Miroslav Reljanović, to roll over a portion of his equity and remain involved, ensuring continuity. Strategically, Permira aims to supercharge Ergomed's "Site Management" model and its pharmacovigilance capabilities through both organic investment and accretive M&A.

ERGOMED, which reported an EBITDA margin of in 2023, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Headquartered in the UK, Ergomed is a differentiated Clinical Research Organization (CRO) providing specialized services to the pharmaceutical industry. Unlike generalist CROs, Ergomed has carved out a deep niche in complex therapeutic areas, specifically Oncology and Rare Diseases. Additionally, through its "PrimeVigilance" division, it is a global leader in pharmacovigilance (drug safety monitoring) and medical information services. The company operates in over 100 countries and serves a mix of small biotechs and large pharma clients.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (GBP)

Year

Rev

EBITDA

EBIT

2023

2022

Similar deals in Healthcare Services

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
05/2024	21 INVEST / OAKLEY CAPITAL INVESTMENTS	PRODUCT LIFE	FRANCE	Healthcare Services
10/2023	MOTION EQUITY PARTNERS	BANOOK	FRANCE	CRO / Clinical Trials
09/2023	CERBA HEALTHCARE	CIRION BIOPHARMA RESEARCH	CANADA	CRO / Clinical Trials
06/2023	SUPERNOVA INVEST / HEAL CAPITAL	GLEAMER	FRANCE	Health Tech
06/2022	ASTORG	OPEN HEALTH	UNITED STATES	Healthcare Services
11/2020	KERSIA	SOPURA	BELGIUM	Sterilization & Hygiene
10/2020	IK PARTNERS	KERSIA	FRANCE	Sterilization & Hygiene
05/2020	CLAYTON, DUBILIER & RICE (CD&R)	HUNTSWORTH	UNITED KINGDOM	Healthcare Services
01/2018	SPECTRIS	CONCEPT LIFE SCIENCES	UNITED KINGDOM	CRO / Clinical Trials
04/2016	CHARLES RIVER LABORATORIES	WIL RESEARCH	UNITED STATES	CRO / Clinical Trials

REFERENCES

Valuation range: EV 500M - 1.5b GBP

EBITDA range: 25M - 50M GBP

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of ERGOMED by PERMIRA are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: permira